

TRANSNASAL TRANSPORTIMMUNISATION WITH HIGHLY ADAPTABLE CARRIERS

Publication number: HU0105400

Publication date: 2002-05-29

Inventor: CEVC GREGOR (DE); CHOPRA AMLA (IN); STIEBER JULIANE (DE)

Applicant: IDEA AG (DE)

Classification:

- international:






A61K47/46; A61K9/00; A61K9/127; A61K38/28;
A61K39/00; A61K39/08; A61K39/10; A61K39/106;
A61K39/112; A61K39/125; A61K39/145; A61K39/155;
A61K39/165; A61K39/21; A61K39/245; A61K39/25;
A61K39/29; A61K39/39; A61K47/36; A61P1/00;
A61P1/04; A61P1/08; A61P3/04; A61P3/10; A61P5/00;
A61P5/06; A61P5/16; A61P5/26; A61P7/00; A61P7/02;
A61P7/04; A61P9/04; A61P9/06; A61P9/08; A61P9/10;
A61P9/12; A61P11/06; A61P13/02; A61P13/12;
A61P15/00; A61P15/08; A61P15/10; A61P17/00;
A61P17/02; A61P17/06; A61P19/00; A61P19/02;
A61P19/08; A61P19/10; A61P21/00; A61P21/04;
A61P23/00; A61P25/08; A61P25/16; A61P25/18;
A61P25/20; A61P25/24; A61P25/26; A61P25/28;
A61P25/30; A61P25/32; A61P27/02; A61P27/16;
A61P29/00; A61P31/04; A61P31/12; A61P33/10;
A61P35/00; A61P37/06; A61P37/08; A61P43/00;
A61K47/46; A61K9/00; A61K9/127; A61K38/19;
A61K38/28; A61K39/00; A61K39/08; A61K39/10;
A61K39/106; A61K39/112; A61K39/125; A61K39/145;
A61K39/155; A61K39/21; A61K39/245; A61K39/29;
A61K39/39; A61K47/36; A61P1/00; A61P3/00;
A61P5/00; A61P7/00; A61P9/00; A61P11/00;
A61P13/00; A61P15/00; A61P17/00; A61P19/00;
A61P21/00; A61P23/00; A61P25/00; A61P27/00;
A61P29/00; A61P31/00; A61P33/00; A61P35/00;
A61P37/00; A61P43/00; (IPC1-7): A61K9/127

- European: A61K9/00M14; A61K9/127B2; A61K38/28; A61K39/39

Application number: HU20010005400 20000126

Priority number(s): EP19990101480 19990127

Also published as:

 EP1031347 (A1)
 WO0044350 (A1)
 MXPA01007659 (A)
 CN1344155 (A)
 CA2360643 (A1)

more >>

Abstract not available for HU0105400

Abstract of corresponding document: **EP1031347**

The invention deals with the transport of preferably large molecules across nasal mucosa by means of specially designed, highly adaptable carriers loaded with said molecules. One of the purposes of making such formulations is to achieve non-invasive systemic delivery of therapeutic polypeptides, proteins and other macromolecules; the other intent is to overcome circumstantially the blood-brain barrier by exploiting the nasal cavity to enter the body and then to get access to the brain. A third intent is to achieve successful protective or tolerogenic immunisation via nasal antigen or allergen administration.

<http://www.esp@cenet.org>

Data supplied from the **esp@cenet** database - Worldwide

Report a data error here